Disease damage and low bone mineral density: An analysis of women with systemic lupus erythematosus ever and never receiving corticosteroids

Rheumatology

Volumn 45, Issue 1, 2006, Pages 53-60

  Lee, C ^a   Almagor, O ^a   Dunlop, D D ^a   Manzi, S ^b   Spies, S ^a   Chadha, A B ^a   Ramsey Goldman, R ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Bone mineral density; Corticosteroids; Disease damage; Osteoporosis; SLE

Indexed keywords

CORTICOSTEROID;

ADULT; AFRICAN AMERICAN; ANAMNESIS; ARTICLE; BONE DENSITY; BONE INJURY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG USE; FEMALE; HIP; HUMAN; LABORATORY TEST; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOLYSIS; OSTEOPOROSIS; OUTPATIENT DEPARTMENT; PATIENT CODING; PHYSICAL EXAMINATION; PREMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADRENAL CORTEX HORMONES; ADULT; BONE DENSITY; BONE DISEASES, METABOLIC; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LIFE STYLE; LUMBAR VERTEBRAE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MENOPAUSE; OSTEOPOROSIS; PELVIC BONES;

EID: 29844439395     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kei079     Document Type: Article

References (42)

1. Trends in deaths from systemic lupus erythematosus - United States, 1979-1998. MMWR Morb Mortal Wkly Rep 2002;51:371-4.
2. Cervera R, Khamashta MA, Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine 2003;82:299-308.
3. Uramoto KM, Michet CJ Jr, Thumboo J, Sunku J, O'Fallon WM, Gabriel SE. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999;42:46-50.
4. Reveille JD, Bartolucci A, Alarcon GS. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum 1990;33:37-48.
5. Harvey AM, Schulman LE, Tomulty PA, Schoenrich EH. Systemic lupus erythematosus. Review of literature and clinical analysis of 138 cases. Medicine 1954;33:291.
6. Halberg P, Bendixen G, Kriegbaum NJ et al. Systemic lupus erythematosus I. Disease manifestations, infections, thrombotic events, causes of death and survival in 173 patients followed for 13.9 years. Ugeskr Laeger 1991;153:1700.
7. Urowitz MB, Gladman DD, Abu-Shakra M, Farewell VT. Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J Rheumatol 1997;24: 1061-5.
8. Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol 2001;13:345-51.
9. Gordon C. Long-term complications of systemic lupus erythematosus. Rheumatology 2002;41:1095-100.
10. Trapani S, Civinini R, Ermini M, Paci E, Falcini F. Osteoporosis in juvenile systemic lupus erythematosus: A longitudinal study on the effect of steroids on bone mineral density. Rheumatol Int 1998; 18:45-9.
11. Sinigaglia L, Varenna M, Binelli L et al. Determinants of bone mass in systemic lupus erythematosus: A cross sectional study on premenopausal women. J Rheumatol 1999;26:1280-4.
12. Kipen Y, Buchbinder R, Forbes A, Strauss B, Littlejohn G, Morand E. Prevalence of reduced bone mineral density in systemic lupus erythematosus and the role of steroids. J Rheumatol 1997; 24:1922-9.
13. Kipen Y, Briganti E, Strauss B, Will R, Littlejohn G, Morand E. Three year followup of bone mineral density change in premenopausal women with systemic lupus erythematosus. J Rheumatol 1999;26:2.
14. Hansen M, Halberg P, Kollerup G et al. Bone metabolism in patients with systemic lupus erythematosus. Effect of disease activity and glucocorticoid treatment. Scand J Rheumatol 1998;27: 197-200.
15. Gilboe I, Kvien TK, Haugeberg G, Husby G. Bone mineral density in systemic lupus erythematosus: Comparison with rheumatoid arthritis and healthy controls. Ann Rheum Dis 2000;59:110-5.
16. Jardinet D, Lefebvre C, Depresseux G, Lambert M, Devogelaer J-P, Houssiau FA. Longitudinal analysis of bone mineral density in premenopausal female systemic lupus erythematosus patients: Deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatol 2000; 39:389-92.
17. Redlich K, Ziegler S, Kiener HP et al. Bone mineral density and biochemical parameters of bone metabolism in female patients with systemic lupus erythematosus. Ann Rheum Dis 2000;59:308-10.
18. Bhattoa HP, Kiss E, Bettembuk P, Balogh A. Bone mineral density, biochemical markers of bone turnover, and hormonal status in men with systemic lupus erythematosus. Rheumatol Int 2001;21: 97-102.
19. Lakshminarayanan S, Walsh S, Mohanraj M, Rothfield N. Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol 2001;28:102-8.
20. Dhillon VB, Davies MC, Hall ML et al. Assessment of the effect of oral corticosteroids on bone mineral density in systemic lupus erythematosus: a preliminary study with dual energy x-ray absorptiometry. Ann Rheum Dis 1990;49:624-6.
21. Kalla AA, Fataar AB, Jessop SJ, Bewerunge L. Loss of trabecular bone mineral density in systemic lupus erythematosus. Arthritis Rheum 1993;30:1726-34.
22. Formiga F, Moga I, Nolla JM, Pac M, Mitjavila F, Roig-Escofet D. Loss of bone mineral density in premenopausal women with systemic lupus erythematosus. Ann Rheum Dis 1995;54:274-6.
23. Houssiau FA, Lefebvre C, Depresseux G, Lambert M, Devogelaer JP, Nagant de Deuxchaisnes C. Trabecular and cortical bone loss in systemic lupus erythematosus. Br J Rheumatol 1996;35:244-7.
24. Tanaka Y, Watanabe K, Suzuki M et al. Spontaneous production of bone-resorbing lymphokines by B cells in patients with systemic lupus erythematosus. J Clin Immunol 1989;9:415-20.
25. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 1991;147:117-23.
26. Al-Janadi M, Al-Balla S, Al-Dalaan A, Raziuddin S. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol 1993;13:58-67.
27. Sels F, Dequeker J, Verwilghen J, Mbuyi-Muamba JM. SLE and osteoporosis: dependence and/or independence on glucocorticoids. Lupus 1996;5:89-92.
28. Pineau CA, Urowitz MB, Fortin PJ, Ibanez D, Gladman DD. Osteoporosis in systemic lupus erythematosus: Factors associated with referral for bone mineral density studies, prevalence of osteoporosis and factors associated with reduced bone density. Lupus 2004; 13:436-41.
29. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
30. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
31. Gladman D, Ginzler E, Goldsmith C et al. Systemic lupus international collaborative clinics: Development of a damage index in systemic lupus erythematosus. J Rheumatol 1992;19:1820-1.
32. Karlson EW, Daltroy LH, Rivest C et al. Validation of a Systemic Lupus Activity Questionnaire (SLAQ) for population studies. Lupus 2003;12:280-6.
33. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. WHO Technical Report Series no. 843, 1994.
34. Tamhane, AC, Dunlop DD. Statistics and data analysis. Upper Saddle River, NJ: Prentice Hall, 2000:475-7.
35. Petri M. Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: An update. Arthritis Care Res 1995;8:137-45.
36. Gogh AKS, Lilley J, Eyre S, Holder RL, Emery P. Generalised bone loss in patients with rheumatoid arthritis. Lancet 1994;344:23-7.
37. Deodhar AA, Brabyn J, Jones PW, Davis MJ, Woolf AD. Longitudinal study of hand bone densitometry in rheumatoid arthritis. Arthritis Rheum 1995;38:1204-10.
38. Sun KH, Yu CL, Tang SJ, Sun GH. Monoclonal anti-doublestranded DNA autoantibody stimulates the expression and release of IL-1 beta, IL-6, IL-8, IL-10 and TNF-alpha from normal human mononuclear cells involving in the lupus pathogenesis. Immunology 2000;99:352-60.
39. Amerio P, Frezzolini A, Abeni D et al. Increased IL-18 in patients with systemic lupus erythematosus: Relations with Th-1, Th-2, pro-inflammatory cytokines and disease activity. IL-18 is a marker of disease activity but does not correlate with pro-inflammatory cytokines. Clin Exp Rheumatol 2002;20:535-8.
40. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002;22:549-53.
41. Gravallese EM. Bone destruction in arthritis. Ann Rheum Dis 2002;61(Suppl. 2):iI84-6.
42. Franchimont N, Reenaers C, Lambert C et al. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. Clin Exp Immunol 2004; 138:491-8.